Improved therapeutic efficacy of a bifunctional anti-C5 mAb-FH SCR1–5 fusion protein over anti-C5 mAb in an accelerated mouse model of C3 glomerulopathy
ImmunoHorizons · 2025
DOI: 10.1093/immhor/vlae006 ↗Kurz gefasst
Fachartikel in der Zeitschrift ImmunoHorizons, 2025. Verfasst von Sayaka Sato und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United …. Hauptthemen laut MEDLINE: Complement C5, Complement C3, Recombinant Fusion Proteins, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, Kira Pharmaceuticals.
Abstract (Originalsprache)
C3 glomerulopathy (C3G), a rare kidney disease caused by dysregulation of alternative pathway complement activation, is characterized by glomerular C3 deposition, proteinuria, crescentic glomerulonephritis, and renal failure. The anti-C5 monoclonal antibody (mAb) drug eculizumab has shown therapeutic effects in some but not all patients with C3G, and no approved therapy is currently available. Here, we developed and used a triple transgenic mouse model of fast progressing lethal C3G (FHm/mP−/−hFDKI/KI) to compare the therapeutic efficacy of a bifunctional anti-C5 mAb fused to a functional factor H (FH) fragment (short consensus repeat 1–5 [SCR1–5]) and the anti-C5 mAb itself. The new C3G mouse model is derived by humanizing factor D (hFDKI/KI) in a previously described FHm/mP−/− mouse that developed lethal C3G. We tested the effectiveness of these 2 complement inhibitors in triple transgenic mice with established C3G and glomerular disease. No FHm/mP−/−hFDKI/KI mice treated with vehicle survived the 30-d study period. All FHm/mP−/−hFDKI/KI mice treated with the C5 mAb-FH SCR1–5 fusion protein and 50% of mice treated with the anti-C5 mAb survived the 30-d treatment period. Moreover, mice treated with the C5 mAb-FH SCR1–5 fusion protein, but not those treated with the anti-C5 mAb, showed restored plasma alternative pathway complement control. The C5 mAb-FH SCR1–5 fusion protein reversed glomerular disease to a greater degree than the anti-C5 mAb. These data suggest that simultaneously inhibiting the terminal and proximal complement pathways, by anti-C5 mAb and FH SCR1–5, respectively, can reverse established C3G and is more efficacious than inhibiting the terminal pathway alone. A similar approach may be effective in treating human C3G.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
ORCID-Profile: Sayaka Sato, Madhu Golla, Wen-Chao Song
Förderung
- NIAID NIH HHS
- NIH HHS
- Kira Pharmaceuticals
- National Institutes of Health
Zitieren
APA
Sato, S., Miwa, T., Gullipalli, D., Golla, M., Mohammadyari, E., Zhou, L., Palmer, M., & Song, W. C. (2025). Improved therapeutic efficacy of a bifunctional anti-C5 mAb-FH SCR1–5 fusion protein over anti-C5 mAb in an accelerated mouse model of C3 glomerulopathy. ImmunoHorizons. https://doi.org/10.1093/immhor/vlae006
Vancouver
Sato S, Miwa T, Gullipalli D, Golla M, Mohammadyari E, Zhou L, et al. Improved therapeutic efficacy of a bifunctional anti-C5 mAb-FH SCR1–5 fusion protein over anti-C5 mAb in an accelerated mouse model of C3 glomerulopathy. ImmunoHorizons. 2025. doi:10.1093/immhor/vlae006
BibTeX
@article{Sato2025,
author = {Sato, Sayaka and Miwa, Takashi and Gullipalli, Damodar and Golla, Madhu and Mohammadyari, Eshagh and Zhou, Lin and Palmer, Matthew and Song, Wen-Chao},
title = {Improved therapeutic efficacy of a bifunctional anti-C5 mAb-FH SCR1–5 fusion protein over anti-C5 mAb in an accelerated mouse model of C3 glomerulopathy},
journal = {ImmunoHorizons},
year = {2025},
doi = {10.1093/immhor/vlae006}
}
EUVIMED